Metastatic basal cell carcinoma with amplification of PD-L1: Exceptional response to anti-PD1 therapy

npj Genomic Medicine

Volumn 1, Issue , 2016, Pages

  Ikeda, Sadakatsu ^a,b,c   Goodman, Aaron M ^a,b   Cohen, Philip R ^b   Jensen, Taylor J ^d   Ellison, Christopher K ^d   Frampton, Garrett ^e   Miller, Vincent ^e   Patel, Sandip P ^a,b   Kurzrock, Razelle ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d SEQUENOM INC   (United States)

^e FOUNDATION MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85015695943     PISSN: None     EISSN: 20567944     Source Type: Journal    
DOI: 10.1038/npjgenmed.2016.37     Document Type: Article

References (32)

1. Gandhi, S. A. & Kampp, J. Skin cancer epidemiology, detection, and management. Med. Clin. North Am. 99, 1323-1335 (2015).
2. Hahn, H. et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85, 841-851 (1996).
3. Adolphe, C., Hetherington, R., Ellis, T. & Wainwright, B. Patched1 functions as a gatekeeper by promoting cell cycle progression. Cancer Res. 66, 2081-2088 (2006).
4. Xie, J. et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 391, 90-92 (1998).
5. Epstein, E. H. Basal cell carcinomas: Attack of the hedgehog. Nat. Rev. Cancer 8, 743-754 (2008).
6. Sekulic, A. et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N. Engl. J. Med. 366, 2171-2179 (2012).
7. Migden, M. R. et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): A multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 16, 716-728 (2015).
8. Sharpe, H. J. et al. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell 27, 327-341 (2015).
9. Atwood, S. X. et al. Smoothened variants explain the majority of drug resistance in basal cell carcinoma. Cancer Cell 27, 342-353 (2015).
10. Zhao, C. et al. Detection of fetal subchromosomal abnormalities by sequencing circulating cell-free DNA from maternal plasma. Clin. Chem. 61, 608-616 (2015).
11. Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015).
12. George T. J. et al. Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer [Abstract]. J. Clin. Oncol. 34 (2016).
13. Green, M. R. et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116, 3268-3277 (2010).
14. Ansell, S. M. et al. PD-1 Blockade with Nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372, 311-319 (2015).
15. Frampton, G. M. et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol. 31, 1023-1031 (2013).
16. Schwaederle, M. et al. Molecular Tumor Board: The University of California San Diego Moores Cancer Center Experience. Oncologist 19, 631-636 (2014).
17. Mohan, S. V., Kuo, K. Y. & Chang A. L. S. Incidental regression of an advanced basal cell carcinoma after ipilimumab exposure for metastatic melanoma. JAAD Case Rep. 2, 13-15 (2016).
18. Winkler J. k. et al. Anti-PD-1 therapy in nonmelanoma skin cancer. Br. J. Dermatol (e-pub ahead of print 8 April 2016; doi:10.1111/bjd.14664).
19. Dong, H. et al. Tumor-Associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat. Med. 8, 793-800 (2002).
20. Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320-330 (2015).
21. Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018-2028 (2015).
22. Straub, M. et al. CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity. Oncotarget 7, 12024-12034 (2016).
23. Barrett, M. T. et al. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget 6, 26483-26493 (2015).
24. Nanda, R. et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J. Clin. Oncol. 34, 2460-2467 (2016).
25. Patel, S. P. & Kurzrock, R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 14, 847-856 (2015).
26. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
27. Schwaederle, M. et al. On the road to precision cancer medicine: Analysis of genomic biomarker actionability in 439 patients. Mol. Cancer Ther. 14, 1488-1494 (2015).
28. Frampton G. M. et al. Assessment of tumor mutation burden from 460, 000 clinical cancer patients using comprehensive genomic profiling [Abstract]. J. Clin. Oncol. 34 (2016).
29. Lefkowitz, R. B. et al. Clinical validation of a noninvasive prenatal test for genomewide detection of fetal copy number variants. Am. J. Obstet. Gynecol. 215, 227.e1-227.e16 (2016).
30. Wheler, J., Lee, J. J. & Kurzrock, R. Unique molecular landscapes in cancer: implications for individualized, curated drug combinations. Cancer Res 74, 7181-7184 (2014).
31. Schwaederle, M. et al. Precision oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Mol. Cancer Ther. 15, 743-752 (2016).
32. Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509-2520 (2015).